The Na+/I- symporter (NIS):: Imaging and therapeutic applications

被引:76
作者
Dadachova, E
Carrasco, N
机构
[1] Albert Einstein Coll Med, Dept Nucl Med, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA
关键词
D O I
10.1053/j.semnuclmed.2003.09.004
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The Na+/I- symporter (NIS) is the plasma membrane glycoprotein that mediates the active uptake of I- in the thyroid, ie, the crucial first step in thyroid hormone biosynthesis. NIS also mediates I- uptake in other tissues, such as salivary glands, gastric mucosa, and lactating (but not nonlactating) mammary gland. The ability of thyroid cancer cells to actively transport I- via NIS provides a unique and effective delivery system to detect and target these cells for destruction with therapeutic doses of radioiodide. Breast cancer is the only malignancy other than thyroid cancer to have been shown to functionally express NIS endogenously. The considerable potential diagnostic and therapeutic use of radiolodide in breast cancer is currently being assessed. On the other hand, exogenous NIS gene transfer has successfully been carried out into a variety of other cell lines and tumors, including A375 human melanoma tumors, and SiHa cervix cancer, human glioma, and hepatoma cell lines. Most notably, significant radioiodine therapy results have been obtained in the NIS-transfected human prostatic adenocarcinoma cell line LNCaP and in NIS-transfected myeloma cells, both of which exhibited prolonged retention of radioiodide even in the absence of I- organification. The therapeutic potential of alternative NIStransported radioisotopes with different decay properties and a shorter, physical half-life than I-131(-), such as beta-emitter (188)Rhenium ((ReO4-)-Re-188) and alpha-emitter (211)Astatine (At-211(-)), has been evaluated. In conclusion, it is clear that the remarkable progress made in the last few years in the molecular characterization of NIS has created new opportunities for the development of diagnostic and therapeutic applications for NIS in nuclear medicine. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:23 / 31
页数:9
相关论文
共 51 条
[1]  
Boland A, 2000, CANCER RES, V60, P3484
[2]   Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers [J].
Boland, A ;
Magnon, C ;
Filetti, S ;
Bidart, JM ;
Schlumberger, M ;
Yeh, P ;
Perricaudet, M .
THYROID, 2002, 12 (01) :19-26
[3]   Sodium-iodide symporter (NIS)-mediated accumulation of [211AT]astatide in NIS-transfected human cancer cells [J].
Carlin, S ;
Mairs, RJ ;
Welsh, P ;
Zalutsky, MR .
NUCLEAR MEDICINE AND BIOLOGY, 2002, 29 (07) :729-739
[4]   IODIDE TRANSPORT IN THE THYROID-GLAND [J].
CARRASCO, N .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1154 (01) :65-82
[5]   Expression and activity of human Na+/I- symporter in human glioma cells by adenovirus-mediated gene delivery [J].
Cho, JY ;
Xing, S ;
Liu, X ;
Buckwalter, TLF ;
Hwa, L ;
Sferra, TJ ;
Chiu, IM ;
Jhiang, SM .
GENE THERAPY, 2000, 7 (09) :740-749
[6]   In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas [J].
Cho, JY ;
Shen, DHY ;
Yang, W ;
Williams, B ;
Buckwalter, T ;
La Perle, KMD ;
Hinkle, G ;
Pozderac, R ;
Kloos, R ;
Nagaraja, H ;
Barth, RF ;
Jhiang, SM .
GENE THERAPY, 2002, 9 (17) :1139-1145
[7]   Rhenium-188 as an alternative to iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS) [J].
Dadachova, E ;
Bouzhzah, B ;
Zuckier, LS ;
Pestell, RG .
NUCLEAR MEDICINE AND BIOLOGY, 2002, 29 (01) :13-18
[8]  
Dadachova E, 2002, J NUCL MED, V43, p120P
[9]   Cloning and characterization of the thyroid iodide transporter [J].
Dai, G ;
Levy, O ;
Carrasco, N .
NATURE, 1996, 379 (6564) :458-460
[10]   Will radioiodine be useful in treatment of breast cancer? [J].
Daniels, GH ;
Haber, DA .
NATURE MEDICINE, 2000, 6 (08) :859-860